Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|State||Published - Mar 25 1987|
ASJC Scopus subject areas
- Cancer Research